Journal
NATURE MEDICINE
Volume 24, Issue 5, Pages 551-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-018-0015-9
Keywords
-
Funding
- German Research Foundation (DFG) [KU 2673/2-1, SPP1629: BI839/5-2, KR1701/5-1, KF0218, HI 865/2-1]
- Bundesministerium far Bildung and Forschung (BMBF) (NGFN- Plus) [01GS0820]
- Helmholtz Association (ICEMED) [WB19]
- Institute of Cardiometabolism and Nutrition
- Assistance Publique Hopitaux de Paris
- Institut Benjamin Delessert
- Charite /Berlin Institute of Health (BIH) Clinical Scientist Program
- Berlin Institute of Health (BIH)
- DFG [SFB740-B6, SFB1078-B6]
- DFG Cluster of Excellence 'Unifying Concepts in Catalysis'
- Wellcome Trust
Ask authors/readers for more resources
Genetic defects underlying the melanocortin-4 receptor (MC4R) signaling pathway lead to severe obesity. Three severely obese LEPR-deficient individuals were administered the MC4R agonist setmelanotide, resulting in substantial and durable reductions in hyperphagia and body weight over an observation period of 45-61 weeks. Compared to formerly developed and tested MC4R agonists, setmelanotide has the unique capability of activating nuclear factor of activated T cell (NFAT) signaling and restoring function of this signaling pathway for selected MC4R variants. Our data demonstrate the potency of setmelanotide in treatment of individuals with diverse MC4R-related pathway deficiencies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
